Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …

Viscoelastic hemostatic assay (VHAs) are whole blood point-of-care tests that have become
an essential method for assaying hemostatic competence in liver transplantation, cardiac …

Earlier variants of SARS-CoV-2 have been associated with hypercoagulability and an
extensive formation of fibrin amyloid microclots, which are considered to contribute to the …

Viscoelastic testing (VET), including thromboelastography and thromboelastometry,
provides a rapid and comprehensive picture of whole blood coagulation dynamics and …

Infection by SARS-CoV-2 is associated with a high risk of thrombosis. The laboratory
documentation of hypercoagulability and impaired fibrinolysis remains a challenge. Our aim …

Early in the coronavirus disease 2019 (COVID-19) pandemic, global governing bodies
prioritized transmissibility-based precautions and hospital capacity as the foundation for …

SARS-CoV-2 infection is associated with frequent thrombotic events, at the micro and macro-
vascular level, due to the perpetuation of a state of hypercoagulability. The so-called 'COVID …

A proportion of people infected with SARS-CoV-2 develop moderate or severe COVID-19,
with an increased risk of thromboembolic complications. The inflammatory response to …

Since December 2019, corona virus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic, posing …

Background: The treatment of COVID-19 patients with heparin is not always effective in
preventing thrombotic complications, but can also be associated with bleeding …